AndreaBozzo/ceres-open-data-index huggingface dataset:
High correlation between the turnover of nucleotides under mutational pressure and the DNA composition

Background
          Any DNA sequence is a result of compromise between the selection and mutation pressures exerted on it during evolution. It is difficult to estimate the relative influence of each of these pressures on the rate of accumulation of substitutions. However, it is important to discriminate between the effect of mutations, and the effect of selection, when studying the phylogenic relations between taxa.
        
        
          Results
          We have tested in computer simulations, and analytically, the available substitution matrices for many genomes, and we have found that DNA strands in equilibrium under mutational pressure have unique feature: the fraction of each type of nucleotide is linearly dependent on the time needed for substitution of half of nucleotides of a given type, with a correlation coefficient close to 1. Substitution matrices found for sequences under selection pressure do not have this property. A substitution matrix for the leading strand of the Borrelia burgdorferi genome, having reached equilibrium in computer simulation, gives a DNA sequence with nucleotide composition and asymmetry corresponding precisely to the third positions in codons of protein coding genes located on the leading strand.
        
        
          Conclusions
          Parameters of mutational pressure allow us to count DNA composition in equilibrium with this mutational pressure. Comparing any real DNA sequence with the sequence in equilibrium it is possible to estimate the distance between these sequences, which could be used as a measure of the selection pressure. Furthermore, the parameters of the mutational pressure enable direct estimation of the relative mutation rates in any DNA sequence in the studied genome.
2013 CMHS Uniform Reporting System (URS) Table for New Jersey

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for New Jersey for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program.  State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
Patent AT-E400530-T1: [Translated] CLEANING PRODUCT FOR CLEANING SOIL OR GROUNDWATER, PROCESS OF PRODUCTION THEREOF, AND PROCESS FOR CLEANING CONTAMINATED SOIL OR GROUNDWATER USING THIS CLEANING PRODUCT

A purifying agent for purifying soil or ground water which comprises a water suspension containing iron composite particles comprising ±-Fe and magnetite, and having an average particle diameter of 0.05 to 0.50 µm, an S content of 3500 to 10000 ppm and an A1 content of 0.10 to 1.50% by weight, and polyaspartic acid or a salt thereof. The purifying agent is capable of decomposing aliphatic organohalogen compounds or aromatic organohalogen compounds contained in the soil or ground water in an efficient, continuous and economical manner.
Program Instruction (PI-10-09)

This Program Instruction (PI) provides instruction to States on the June 30, 2010, submission of the Annual Progress and Services Report (APSR) required under Title IV-B of the Social Security Act (the Act) for the Stephanie Tubbs Jones Child Welfare Services (CWS) and Promoting Safe and Stable Families (PSSF) Programs, the Child Abuse Prevention and Treatment Act (CAPTA) State Grant Program; and the Chafee Foster Care Independence Program (CFCIP) and the Education and Training Vouchers (ETV) Program; and the CFS-101, Part I, Annual Budget Request, Part II, Annual Summary of Child and Family Services, and Part III, Annual Expenditure Report—Title IV-B, subparts 1 and 2, CFCIP, and ETV.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 525801: N-(4-Methoxyphenyl)-N'-(4-ethoxyphenyl)formamidine

Chemical compound data from PubChem database. IUPAC Name: N'-(4-ethoxyphenyl)-N-(4-methoxyphenyl)methanimidamide. Molecular Formula: C16H18N2O2. Molecular Weight: 270.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
National Youth in Transition Database - Served Populations

States report information from two reporting populations: (1) The Served Population which is information on all youth receiving at least one independent living services paid or provided by the Chafee Program agency, and (2) Youth completing the NYTD Survey.  States  survey youth regarding six outcomes: financial self-sufficiency, experience with homelessness, educational attainment, positive connections with adults, high-risk behaviors, and access to health insurance. States collect outcomes information by conducting a survey of youth in foster care on or around their 17th birthday, also referred to as the baseline population. States will track these youth as they age and conduct a new outcome survey on or around the youth's 19th birthday; and again on or around the youth's 21st birthday, also referred to as the follow-up population. States will collect outcomes information on these older youth at ages 19 or 21 regardless of their foster care status or whether they are still receiving independent living services from the State. Depending on the size of the State's foster care youth population, some States may conduct a random sample of the baseline population of the 17-year-olds that participate in the outcomes survey so that they can follow a smaller group of youth as they age. All States will collect and report outcome information on a new baseline population cohort every three years.

<b>Units of Response: </b>Current and former youth in foster care

<b>Type of Data: </b>Administrative

<b>Tribal Data: </b>No

<b>Periodicity: </b>Annual

<b>Demographic Indicators: </b>Ethnicity;Race;Sex

<b>SORN: </b>Not Applicable

<b>Data Use Agreement: </b>https://www.ndacan.acf.hhs.gov/datasets/request-dataset.cfm

<b>Data Use Agreement Location: </b>https://www.ndacan.acf.hhs.gov/datasets/order_forms/termsofuseagreement.pdf

<b>Granularity: </b>Individual

<b>Spatial: </b>United States

<b>Geocoding: </b>FIPS Code
Treatment Episode Data Set (TEDS) 1992-2002 National Admissions to Substance Abuse Treatment Services

This report presents results from the Treatment Episode Data Set (TEDS) for 2002 and trend data for 1992-2002. The report provides information on the demographic and substance abuse characteristics of the 1.9 million people admitted to treatment for abuse of alcohol and drugs in 2002 to facilities that report to individual state administrative data systems.
Patent AT-E401492-T1: [Translated] DRIVE DEVICE FOR ROTATING OSCILLATIONAL TOOLS AND TOOL HEREOF

A carrier bush (15) fits on bearings in a drive casing (11) so as to rotate. A drive shaft (13) rotates on bearings in the carrier bush. A tool mount (16A,16B) holds processing tools. A vibration-stimulating device generates vibration overlay for the tool mount. An independent claim is also included for a tool with a drive device.
Mycosin-1, a subtilisin-like serine protease of

Background
          Exported proteases are commonly associated with virulence in bacterial pathogens, yet there is a paucity of information regarding their role in Mycobacterium tuberculosis. There are five genes (mycP1-5) present within the genome of Mycobacterium tuberculosis H37Rv that encode a family of secreted, subtilisin-like serine proteases (the mycosins). The gene mycP1 (encoding mycosin-1) was found to be situated 3700 bp (four ORF's) from the RD1 deletion region in the genome of the attenuated vaccine strain M. bovis BCG (bacille de Calmette et Guérin) and was selected for further analyses due to the absence of expression in this organism.
        
        
          Results
          Full-length, 50 kDa mycosin-1 was observed in M. tuberculosis cellular lysates, whereas lower-molecular-weight species were detected in culture filtrates. A similar lower-molecular-weight species was also observed during growth in macrophages. Mycosin-1 was localized to the membrane and cell wall fractions in M. tuberculosis by Western blotting, and to the cell envelope by electron microscopy. Furthermore, M. tuberculosis culture filtrates were shown to contain a proteolytic activity inhibited by mixed serine/cysteine protease inhibitors and activated by Ca2+, features typical of the subtilisins.
        
        
          Conclusions
          Mycosin-1 is an extracellular protein that is membrane- and cell wall-associated, and is shed into the culture supernatant. The protein is expressed after infection of macrophages and is subjected to proteolytic processing. Although proteolytically active mycosin-1 could not be generated recombinantly, serine protease activity containing features typical of the subtilisins was detected in M. tuberculosis culture filtrates.
Compound 526592: 2,4'-Bis(trimethylsilyloxy)diphenylmethane

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[2-[(4-trimethylsilyloxyphenyl)methyl]phenoxy]silane. Molecular Formula: C19H28O2Si2. Molecular Weight: 344.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Oregon Medicaid Dental Services

Effective Jan. 1, 2026. Copyright Notice: Current Dental Terminology © 2025 American Dental Association. All rights reserved.  

Where applicable, please refer to Oregon Administrative Rules, Prioritized List placement and Guideline Notes listed for each code for complete information regarding benefit coverage and limitations.

Dental/Denturist Services Rules (Chapter 410, Division 123): https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=1711 

Early and Periodic Screening, Diagnostic and Treatment (EPSDT) Rules (Chapter 410, Division 151): https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=8155 

Prioritized List and Guideline Notes: https://www.oregon.gov/oha/hpa/dsi-herc/Pages/index.aspx

For medical-surgical services, refer to the code groups at https://www.oregon.gov/oha/HSD/OHP/Pages/Policy-Medical-Surgical.aspx. 

To find fee-for-service reimbursement rates, view the OHP Fee-for-Service Fee Schedule at http://www.oregon.gov/oha/hsd/ohp/pages/fee-schedule.aspx. This schedule represents a given point in time and may not include payable codes that were added to MMIS after the posted fee schedule date.
MD COVID-19 - Total Cases Statewide

<b>Note:</b> Starting April 27, 2023 updates change from daily to weekly.

<b>Summary</b>
The cumulative number of positive COVID-19 cases among Maryland residents.

<b>Description</b>
The MD COVID-19 - Total Cases Statewide data layer is a collection of the statewide positive COVID-19 test results that have been reported each day by each local health department via the ESSENCE system.

<b>Terms of Use</b>
The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.
Beat-to-beat changes in stroke volume precede the general circulatory effects of mechanical ventilation: a case report

Background:
          The haemodynamic as well as the ventilatory consequences of mechanical ventilation can be harmful in critically ill neonates. Newly developed ventilatory lung protective strategies are not always available immediately and in an acute situation the haemodynamic changes caused by mechanical ventilation can affect the oxygen delivery considerably. We report the case of a male neonate who was treated with conventional pressure-controlled mechanical ventilation because of respiratory distress and progressive respiratory acidosis resulting from meconium aspiration. Because of poor arterial oxygenation despite 100% inspired oxygen and increased ventilator settings, echocardiography was performed to exclude central haemodynamic reasons for low oxygen delivery.
        
        
          Method:
          Doppler echocardiography was used for the measurement of stroke volume and cardiac output. Pulse oximetry and aortic blood pressure were monitored continuously.
        
        
          Results:
          Echocardiography revealed no cardiac malformations or signs of persistent fetal circulation. When inspiratory pressures and duration were increased, beat-to-beat variation in stroke volume preceded decay in cardiac output. Stroke volume variations and oxygen saturation values guided ventilator settings until extracorporal membrane oxygenation could be arranged for. After recovery and discharge 4 weeks later the boy is progressing normally.
        
        
          Conclusion:
          Because oxygen delivery is dependent on both blood flow and arterial oxygen content, measurement of cardiac output as well as left heart oxygen saturation is a useful guide to optimizing oxygen delivery. This case report demonstrates how Doppler echocardiographic monitoring of beat-to-beat changes in stroke volume can be used to detect early negative haemodynamic effects of increased mechanical ventilation settings before cardiac output is affected.
Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillation

Objective
          To estimate the mortality rate of patients newly diagnosed with chronic atrial fibrillation (AF) and compare it with the one in the general population. To evaluate the role of co-morbidity and other factors on the risk of dying among AF patients.
        
        
          Methods
          We used the General Practice Research Database in the UK to perform a retrospective cohort study. We followed a cohort of chronic AF patiens (N = 1,035) and an age and sex matched cohort of 5,000 subjects sampled from the general population. We used all deceased AF patients as cases (n = 234) and the remaining AF patients as controls to perform a nested case-control analysis. We estimated mortality risk associated with AF using Cox regression. We computed mortality relative risks using logistic regression among AF patients.
        
        
          Results
          During a mean follow-up of two years, 393 patients died in the general population cohort and 234 in the AF cohort. Adjusted relative risk of death in the cohort of AF was 2.5 (95%CI 2.1 – 3.0) compared to the general population. Among AF patients, mortality risk increased remarkably with advancing age. Smokers carried a relative risk of dying close to threefold. Ischaemic heart disease was the strongest clinical predictor of mortality with a RR of 3.0 (95% CI; 2.1–4.1). Current use of calcium channel blockers, warfarin and aspirin was associated with a decreased risk of mortality.
        
        
          Conclusions
          Chronic AF is an important determinant of increased mortality. Major risk factors for mortality in the AF cohort were age, smoking and cardiovascular co-morbidity, in particular ischaemic heart disease.
Treatment Episode Data Set (TEDS) 1996-2006 National Admissions to Substance Abuse Treatment Services

This report presents results from the Treatment Episode Data Set (TEDS) for 2006 and trend data for 1996-2006. The report provides information on the demographic and substance abuse characteristics of the 1.8 million people admitted to treatment for abuse of alcohol and/or drugs in 2006 to facilities that report to individual state administrative data systems.
Patent AT-E400287-T1: [Translated] LOW DOSE LHRH ANTAGONISTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES, IN PARTICULAR ALZHEIMER'S DISEASE

The present invention relates to the treatment of dementia and neurodegenerative diseases like Alzheimer's disease with intermediate doses of LHRH antagonists which do not cause a castration. A preferred LHRH antagonist is cetrorelix.
Th1 and Th2 cytokines regulate proteoglycan-specific autoantibody isotypes and arthritis

BALB/c mice immunized with human cartilage proteoglycan (PG) develop arthritis accompanied by the production of autoantibodies to mouse cartilage PG. To determine whether the autoantibody isotype contributes to the onset and severity of arthritis, PG-specific serum IgG1 (Th2, IL-4-cytokine-supporting) and IgG2a (Th1, IFN-γ-controlling) concentrations were monitored during immunization with PG in IL-4-deficient and IFN-γ-deficient mice. Paradoxically, despite elevated IFN-γ, the PG-specific IgG1 isotype was significantly higher than the PG-specific IgG2a response, and the PG-specific IgG1 isotype was independent of IL-4. In contrast, the serum concentration of PG-specific IgG2a isotype was six times higher in IL-4-deficient mice than in wild-type controls. Moreover, the high concentration of PG-specific IgG2a isotype in IL-4-deficient mice corresponded to an increased severity of arthritis. The concentration of PG-specific IgG2a isotype was lower in IFN-γ-deficient mice than in wild-type mice, and the incidence and severity of arthritis also were significantly lower. Concentrations of PG-specific IgG2a isotype autoantibody correlated with the onset and severity of arthritis, suggesting a pathological role of this isotype, probably locally in the joint.
Expression of the C5a receptor (CD88) on granulocytes and monocytes in patients with severe sepsis

Introduction
          Treatment of patients with severe sepsis with agents antagonising the effects of C5a has been proposed based on beneficial effects in animal experiments and in vitro studies demonstrating upregulation of the C5a receptor (CD88) on granulocytes by endotoxin.
        
        
          Materials and methods
          CD88 expression on leukocytes from 12 patients with severe sepsis or septic shock was analysed by flow cytometer, and serum complement factors C3a and C5b-9 were measured by enzyme immunoassay techniques.
        
        
          Results
          The granulocyte CD88 expression on day 1 was lowered (36; range, 2–59) in comparison with controls (63; range, 25–88) (P < 0.001), despite complement activation, while the monocyte CD88 expression was unchanged. The receptor reduction correlated significantly to the APACHE II score (r2 = 0.35, P < 0.05). The recovery of CD88 expression was slow.
        
        
          Discussion
          In contrast to the findings in animals, it is concluded that granulocyte CD88 expression is reduced at the time when the diagnosis of severe sepsis or septic shock can clinically be made. The reason for this needs further investigation but it may be due to a previous complement activation or to cytokine effects.
Results from the 2012 National Survey on Drug Use and Health: Mental Health Findings and Detailed Tables

This report and the detailed tables present results pertaining to mental health from the 2012 National Survey on Drug Use and Health (NSDUH), an annual survey of the civilian, noninstitutionalized population of the United States aged 12 years old or older. Both the report and detailed tables present national estimates of the prevalence of past year mental disorders and past year mental health service utilization for youths aged 12 to 17 and adults aged 18 or older. Among adults, estimates presented include rates and numbers of persons with any mental illness (AMI), serious mental illness (SMI), suicidal thoughts and behavior, major depressive episode (MDE), treatment for depression (among adults with MDE), and mental health service utilization. Estimates for youths include MDE, treatment for depression (among youths with MDE), and mental health service utilization. Measures related to the co-occurrence of mental disorders with substance use or with substance use disorders also are presented for both adults and youths. The report and detailed tables focus mainly on trends between 2011 and 2012 and differences across population subgroups in 2012.
Compound 528142: 5-Isopropyl-3-methyl-2-(phenylthio)pyrazine

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-2-phenylsulfanyl-5-propan-2-ylpyrazine. Molecular Formula: C14H16N2S. Molecular Weight: 244.36. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Posaconazole

Posaconazole is an intravenous antifungal medication used to treat fungal infections. This generic drug, manufactured by Glenmark Pharmaceuticals Inc., USA, comes as a 300 mg/16.7 mL (18 mg/mL) solution in a vial. Approved under ANDA217553, it belongs to the azole antifungal class and is available by prescription since July 2024. This information was generated using AI and is provided for informational and research purposes only.
Revealing the Structural and Chemical Properties of Copper-based Nanoparticles Released from Copper Treated Wood-Dataset

Copper-based preservatives consisting of micronized and nanoscale copper particles have been widely used in applications for wood protection. The presence of micronized/nanoscale particles and soluble aqueous copper in copper-treated wood has raised questions regarding the forms of released particles and the potential hazards of exposure during the use of these products. However, the lack of a comprehensive understanding of the chemistry of these Cu species is limiting the future investigation of the toxicity of these materials and their potential health impact on workers. In this work, we used a combination of scanning transmission electron microscope (STEM) and electron energy loss spectroscopy (EELS) to analyze the particles released during the sanding/sawing of copper-treated lumber. We have demonstrated using EELS Cu L2,3 edges with comparative reference spectra to determine the Cu species. Three types of species, including basic copper carbonate (BCC), Cu(0), and Cu(II)-Wood complex, were identified in released wood dust particles. The unbound copper particles also exist as a form of BCC or reduced Cu(0). The morphologies and chemical states of emitted copper particles indicate the potential chemical transformation due to copper-wood interactions.
Behavioral Health Barometer: New Mexico, 2014

This is a behavioral health report for the state of New Mexico. It uses the  National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.